Critical issues in the antisense inhibition of brain gene expression in vivo: Experiences targetting the 5-HT1A receptor
- 1 September 1997
- journal article
- Published by Elsevier in Neurochemistry International
- Vol. 31 (3) , 349-362
- https://doi.org/10.1016/s0197-0186(96)00106-4
Abstract
No abstract availableKeywords
This publication has 46 references indexed in Scilit:
- Modified oligonucleotides as therapeutic and diagnostic agentsCurrent Opinion in Biotechnology, 1995
- Chronic buspirone treatment differentially regulates 5-HT1A and 5-HT2A receptor mRNA and binding sites in various regions of the rat hippocampusMolecular Brain Research, 1995
- Repeated ECS differentially affects rat brain 5-HT1A and 5-HT2A receptor expressionNeuroReport, 1995
- Binding, uptake, and intracellular trafficking of phosphorothioate-modified oligodeoxynucleotides.Journal of Clinical Investigation, 1995
- The application of antisense oligonucleotide technology to the brain: Some pitfallsCellular and Molecular Neurobiology, 1994
- Antisense oligonucleotide eliminates in vivo expression of c-fos in mammalian brainEuropean Journal of Pharmacology: Molecular Pharmacology, 1992
- Cellular uptake and intracellular fate of antisense oligonucleotidesTrends in Cell Biology, 1992
- Serotonin Receptor Subtypes: Implications for PsychopharmacologyThe British Journal of Psychiatry, 1991
- Stability of antisense DNA oligodeoxynucleotide analogs in cellular extracts and seraLife Sciences, 1991
- Oligodeoxynucleoside phosphorothioate stability in subcellular extracts, culture media, sera and cerebrospinal fluidJournal of Biochemical and Biophysical Methods, 1990